Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms

J. Wang, T. Ishii, W. Zhang, S. Sozer, Y. Dai, J. Mascarenhas, V. Najfeld, Z. J. Zhao, R. Hoffman, N. Wisch, M. Xu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34 + cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34 + cells. The numbers of MC progenitors assayed from MPN CD34 + cells were, however, similar to that assayed from normal CD34 + cells. A higher percentage of the cultured MPN MCs expressed FcεRIα, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F positive MC colonies were assayable from the PB CD34 + cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.

Original languageEnglish (US)
Pages (from-to)1577-1586
Number of pages10
JournalLeukemia
Volume23
Issue number9
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Mast Cells
Neoplasms
Polycythemia Vera
Blood Cells
Primary Myelofibrosis
Stem Cells
Hematologic Neoplasms
Chromosome Aberrations

Keywords

  • JAK2V617F
  • Mast cell
  • MplW515L
  • Myeloproliferative neoplasms

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. / Wang, J.; Ishii, T.; Zhang, W.; Sozer, S.; Dai, Y.; Mascarenhas, J.; Najfeld, V.; Zhao, Z. J.; Hoffman, R.; Wisch, N.; Xu, M.

In: Leukemia, Vol. 23, No. 9, 09.2009, p. 1577-1586.

Research output: Contribution to journalArticle

Wang, J, Ishii, T, Zhang, W, Sozer, S, Dai, Y, Mascarenhas, J, Najfeld, V, Zhao, ZJ, Hoffman, R, Wisch, N & Xu, M 2009, 'Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms', Leukemia, vol. 23, no. 9, pp. 1577-1586. https://doi.org/10.1038/leu.2009.85
Wang, J. ; Ishii, T. ; Zhang, W. ; Sozer, S. ; Dai, Y. ; Mascarenhas, J. ; Najfeld, V. ; Zhao, Z. J. ; Hoffman, R. ; Wisch, N. ; Xu, M. / Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. In: Leukemia. 2009 ; Vol. 23, No. 9. pp. 1577-1586.
@article{a920347f6ad24328bddf86634b21f1e7,
title = "Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms",
abstract = "The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34 + cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34 + cells. The numbers of MC progenitors assayed from MPN CD34 + cells were, however, similar to that assayed from normal CD34 + cells. A higher percentage of the cultured MPN MCs expressed FcεRIα, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F positive MC colonies were assayable from the PB CD34 + cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.",
keywords = "JAK2V617F, Mast cell, MplW515L, Myeloproliferative neoplasms",
author = "J. Wang and T. Ishii and W. Zhang and S. Sozer and Y. Dai and J. Mascarenhas and V. Najfeld and Zhao, {Z. J.} and R. Hoffman and N. Wisch and M. Xu",
year = "2009",
month = "9",
doi = "10.1038/leu.2009.85",
language = "English (US)",
volume = "23",
pages = "1577--1586",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms

AU - Wang, J.

AU - Ishii, T.

AU - Zhang, W.

AU - Sozer, S.

AU - Dai, Y.

AU - Mascarenhas, J.

AU - Najfeld, V.

AU - Zhao, Z. J.

AU - Hoffman, R.

AU - Wisch, N.

AU - Xu, M.

PY - 2009/9

Y1 - 2009/9

N2 - The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34 + cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34 + cells. The numbers of MC progenitors assayed from MPN CD34 + cells were, however, similar to that assayed from normal CD34 + cells. A higher percentage of the cultured MPN MCs expressed FcεRIα, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F positive MC colonies were assayable from the PB CD34 + cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.

AB - The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34 + cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34 + cells. The numbers of MC progenitors assayed from MPN CD34 + cells were, however, similar to that assayed from normal CD34 + cells. A higher percentage of the cultured MPN MCs expressed FcεRIα, CD63 and CD69 than normal MCs, suggesting that cultured MPN MCs are associated with an increased state of MC activation. Further analysis showed that a higher proportion of cultured PV and PMF MCs underwent apoptosis in vitro. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, we showed that the malignant process involved MPN MCs. JAK2V617F positive MC colonies were assayable from the PB CD34 + cells of each of the 17 JAK2V617F positive MPN patients studied. Furthermore, erlotinib, a JAK2 inhibitor, was able to inhibit JAK2V617F-positive PV MC progenitor cells, indicating that malignant MC progenitor cells are a potential cellular target for such JAK2 inhibitor-directed therapy.

KW - JAK2V617F

KW - Mast cell

KW - MplW515L

KW - Myeloproliferative neoplasms

UR - http://www.scopus.com/inward/record.url?scp=70349306855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349306855&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.85

DO - 10.1038/leu.2009.85

M3 - Article

VL - 23

SP - 1577

EP - 1586

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -